Chemical Biology for Understanding Matrix Metalloproteinase Function

被引:49
作者
Knapinska, Anna [1 ,2 ]
Fields, Gregg B. [1 ,2 ]
机构
[1] Torrey Pines Inst Mol Studies, Dept Chem, Port St Lucie, FL 34987 USA
[2] Torrey Pines Inst Mol Studies, Dept Biol, Port St Lucie, FL 34987 USA
基金
美国国家卫生研究院;
关键词
activity-based protein profiling; cell-penetrating peptides; FRET; matrix metalloproteinases; optical imaging; triple-helical peptides; CELL PENETRATING PEPTIDES; ACTIVITY IN-VIVO; PROTEASE ACTIVITY; FLUORESCENT PHOTOPROBE; FLUOROGENIC SUBSTRATE; PHOTOAFFINITY PROBE; CONTRAST AGENT; CLEAVAGE SITE; TUMOR; ROLES;
D O I
10.1002/cbic.201200298
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The matrix metalloproteinase (MMP) family has long been associated with normal physiological processes such as embryonic implantation, tissue remodeling, organ development, and wound healing, as well as multiple aspects of cancer initiation and progression, osteoarthritis, inflammatory and vascular diseases, and neurodegenerative diseases. The development of chemically designed MMP probes has advanced our understanding of the roles of MMPs in disease in addition to shedding considerable light on the mechanisms of MMP action. The first generation of protease-activated agents has demonstrated proof of principle as well as providing impetus for in vivo applications. One common problem has been a lack of agent stability at nontargeted tissues and organs due to activation by multiple proteases. The present review considers how chemical biology has impacted the progress made in understanding the roles of MMPs in disease and the basic mechanisms of MMP action.
引用
收藏
页码:2002 / 2020
页数:19
相关论文
共 134 条
[1]   Probing the Activity of Matrix Metalloproteinase II with a Sequentially Click-Labeled Silica Nanoparticle FRET Probe [J].
Achatz, Daniela E. ;
Mezo, Gabor ;
Kele, Peter ;
Wolfbeis, Otto S. .
CHEMBIOCHEM, 2009, 10 (14) :2316-2320
[2]   Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides [J].
Aguilera, Todd A. ;
Olson, Emilia S. ;
Timmers, Margaret M. ;
Jiang, Tao ;
Tsien, Roger Y. .
INTEGRATIVE BIOLOGY, 2009, 1 (5-6) :371-381
[3]   Detection of MMP-2 and MMP-9 Activity in Vivo with a Triple-Helical Peptide Optical Probe [J].
Akers, Walter J. ;
Xu, Baogang ;
Lee, Hyeran ;
Sudlow, Gail P. ;
Fields, Gregg B. ;
Achilefu, Samuel ;
Edwards, W. Barry .
BIOCONJUGATE CHEMISTRY, 2012, 23 (03) :656-663
[4]   Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth doxorubicin with less toxicity [J].
Albright, CF ;
Graciani, N ;
Han, W ;
Yue, E ;
Stein, R ;
Lai, ZH ;
Diamond, M ;
Dowling, R ;
Grimminger, L ;
Zhang, SY ;
Behrens, D ;
Musselman, A ;
Bruckner, R ;
Zhang, MZ ;
Jiang, X ;
Hu, D ;
Higley, A ;
DiMeo, S ;
Rafalski, M ;
Mandlekar, S ;
Car, B ;
Yeleswaram, S ;
Stern, A ;
Copeland, RA ;
Combs, A ;
Seitz, SP ;
Trainor, GL ;
Taub, R ;
Huang, P ;
Oliff, A .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (05) :751-760
[5]   Discovering disease-associated enzymes by proteome reactivity profiling [J].
Barglow, KT ;
Cravatt, BF .
CHEMISTRY & BIOLOGY, 2004, 11 (11) :1523-1531
[6]   Differential modulation of human melanoma cell metalloproteinase expression by α2β1 integrin and CD44 triple-helical ligands derived from type IV collagen [J].
Baronas-Lowell, D ;
Lauer-Fields, JL ;
Borgia, JA ;
Sferrazza, GF ;
Al-Ghoul, M ;
Minond, D ;
Fields, GB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (42) :43503-43513
[7]  
Baronas-Lowell Diane, 2007, V386, P167, DOI 10.1007/978-1-59745-430-8_6
[8]   Convenient fluorometric assay for matrix metalloproteinase activity and its application in biological media [J].
Beekman, B ;
Drijfhout, JW ;
Bloemhoff, W ;
Ronday, HK ;
Tak, PP ;
Koppele, JMT .
FEBS LETTERS, 1996, 390 (02) :221-225
[9]   Highly increased levels of active stromelysin in rheumatoid synovial fluid determined by a selective fluorogenic assay [J].
Beekman, B ;
vanEl, B ;
Drijfhout, JW ;
Ronday, HK ;
TeKoppele, JM .
FEBS LETTERS, 1997, 418 (03) :305-309
[10]  
Berger Alicia B, 2004, Am J Pharmacogenomics, V4, P371, DOI 10.2165/00129785-200404060-00004